Basal cell carcinoma has an excellent survival rate – especially when the cancer is detected early. Most tumors respond favorably to treatment. Statistics show that:
- The earlier basal cell carcinoma is diagnosed, the better the patient’s chance of survival.
- The therapies that are currently used for basal cell carcinoma offer an 85 to 95 percent recurrence-free cure rate. This means that the specific lesion being treated is effectively cured by the first round of treatment.
- The mortality rate for nonmelanoma skin cancers (including basal cell carcinoma) has been decreasing steadily in recent years.
Although basal cell carcinoma is often curable, people who are diagnosed with one basal cell carcinoma may develop additional lesions elsewhere on their skin later on in life. Recurrent basal cell carcinomas are also highly treatable; oncologists may use the same therapies that they used for the first cancer, or they may recommend different approaches if they believe other options might be more effective.
At Moffitt Cancer Center, we offer a number of innovative treatments for basal cell carcinoma, all in one convenient location. To provide each patient with the best possible treatment plan, a multispecialty team of experts will review the details of his or her case, then recommend the therapies that offer the best outcomes and improved quality of life. Because of our multispecialty approach to cancer treatment and our robust treatment offerings, Moffitt continues to see survival rates that exceed the national averages.
Patients never need a referral to seek care from Moffitt’s Cutaneous Oncology Program. To speak with one of our experienced oncologists about the basal cell carcinoma survival rate and the most appropriate treatments, call 1-888-663-3488 or complete a new patient registration form.